arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Denali Therapeutics Inc.

DNLI

$24.82 ▲ +0.08 (+0.32%) at close

11 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Denali Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.3B

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -43.3% ↘

FCF / Share $-2.44 ↘

Trailing P/E —

Price / Book 3.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-512.54M

↓ -21.2% —

Operating Margin Operating profit as % of sales

-59.5%

↑ +81.1% —

FCF / Share Free cash flow per share

$-2.44

↓ -10.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue Growth YoY (%)	—	N/M	204.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2459%)	122.9% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1436%)	-85.5% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1169%)	1158.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+14377%)	-79.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1092%)	—	—	—	—
EPS Growth YoY (%)	-15.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-142.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	59.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-8.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—	—	—	—
Net Income Growth YoY (%)	-21.2% Weak ↑ Weak Improving Year-over-year change in net income	-191.1% Weak ↓ Weak Declining Year-over-year change in net income	55.5% Excellent Excellent Year-over-year change in net income	-12.2% Weak Weak Year-over-year change in net income	N/M	N/M	-445.3% Weak ↓ Weak Declining Year-over-year change in net income	58.9% Excellent Excellent Year-over-year change in net income	-1.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-10.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	18.1% Good ↑ Good Improving Year-over-year change in free cash flow	-29.1% Weak Weak Year-over-year change in free cash flow	-15.6% Weak Weak Year-over-year change in free cash flow	N/M	N/M	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	-0.5% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	59.6% Excellent Excellent Compound annual revenue growth over 3 years	-27.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	—	20.7% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Operating Margin (%) (%)	—	—	-59.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-497%)	-314.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2194%)	—	18.7% Good Good Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+25%)	—	-35.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-339%)	—	—	—
Profit Margin (%) (%)	—	—	-43.9% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-466%)	-300.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2605%)	—	21.2% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+77%)	—	-28.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-334%)	—	—	—
FCF Margin (%) (%)	—	—	-112.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-242.1% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-451.9% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	123.1% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	36.2% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—
FCF / Net Income (x)	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	2.55x Excellent → Excellent Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	5.81x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-1.29x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Return on Invested Capital (%)	-43.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.1% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-25.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	4.3% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	-42.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	73.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-48.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	3.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-38.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-18.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-50.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-437%)	-34.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-329%)	-14.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-194%)	-31.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-308%)	-30.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-301%)	6.2% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-59%)	-50.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-434%)	-6.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-18.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-226%)	92.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+514%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Net Debt (USD)	$-205.33M	$-174.96M	$-127.11M	$-218.04M	$-293.48M	$-507.14M	$-79.45M	$-77.12M	$-218.38M	$-39.85M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$2.41	$0.86	$0.40	$3.08	$0.28	—	—	—	—
Basic EPS, GAAP (USD)	$-2.97	$-2.57	$-1.06	$-2.60	$-2.39	$0.65	$-2.07	—	—	—	—
Free Cash Flow per Share (USD)	$-2.44	$-2.21	$-2.70	$-2.09	$-1.81	$3.79	$-1.77	—	—	—	—
Book Value per Share (USD)	$6.49	$8.53	$7.45	$7.67	$7.87	$9.55	$4.11	$5.78	$5.32	—	—
Tangible Book Value per Share (USD)	$6.49	$8.53	$7.45	$7.67	$7.87	$9.55	$4.11	$5.78	$5.32	—	—
Basic Weighted Avg Shares (shares)	172.65M	164.47M	137.37M	125.53M	121.52M	108.97M	95.61M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Working Capital (USD)	$802.31M	$762.23M	$986.15M	$1.01B	$518.99M	$1.42B	$384.69M	$448.05M	$395.44M	—	—
Total Equity (USD)	$1.01B	$1.23B	$1.03B	$1.04B	$962.29M	$1.15B	$394.89M	$546.85M	$465.80M	$-94.15M	$-15.63M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$330.53M	$108.46M	$48.66M	$335.66M	$26.68M	$129.16M	$0.00	$0.00	—
Depreciation Expense (USD)	$11.18M	$7.79M	$16.73M	$10.38M	$8.59M	$8.53M	$7.99M	$7.42M	$3.08M	$1.47M	—
Net Income, GAAP (USD)	$-512.54M	$-422.77M	$-145.22M	$-325.99M	$-290.58M	$71.14M	$-197.61M	$-36.24M	$-88.19M	$-86.65M	—
Operating Cash Flow (USD)	$-412.60M	$-347.69M	$-357.99M	$-244.72M	$-211.39M	$416.15M	$-151.58M	$50.12M	$-76.64M	$-71.91M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 39 quarters

Denali Therapeutics Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare DNLI with peers